- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07625566
Anodal tDCS Over Left PPC Enhances Visuospatial Attention and Alpha Power Among Young Adults
Background: Visuospatial attention enables individuals to detect and process relevant stimuli efficiently. The posterior parietal cortex (PPC), a core hub of the dorsal attention network, exerts top-down control over visual scanning and is closely linked to alpha-band oscillations (8-13 Hz), which index attentional allocation and inhibition of distractors. Transcranial direct current stimulation (tDCS) offers a noninvasive method to alter cortical excitability transiently, but evidence for its effects on PPC-mediated attention and alpha power remains mixed.
Objective: This randomized, single-blind trial examined whether anodal tDCS over the left PPC modulates visuospatial attention and resting-state alpha power in young adults, and whether EEG changes predict behavioral performance.
Method: Thirty-two healthy participants (18-40 years) were randomized to anodal (2 mA, 20 min; n=15) or sham (n=17) stimulation. Cancellation Test performance and resting-state EEG were assessed pre- and post-stimulation. EEG analyses focused on artifact-free alpha power; regression models probed associations between neural and behavioral changes.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
İ̇stanbul
-
Beykoz, İ̇stanbul, Turquie (Türkiye), 34820
- Istanbul Medipol University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
La description
Inclusion Criteria:
- Age between 18 and 40 years
- Score of 21 or higher on the Montreal Cognitive Assessment Scale (MoCA)
Exclusion Criteria:
- History of neurological or psychiatric illness
- Uncorrected visual impairments
- MoCA score of 21 or lower
- Use of medications affecting cortical excitability
- History of seizures or epilepsy
- Presence of intracranial metal objects, implanted stimulating devices, or pacemakers
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Anodal tDCS Group
|
Anodal tDCS Protocol: In the Anodal tDCS participant group, a direct current of 2 mA was applied for 20 minutes in accordance with the safety guidelines.
To provide cortical stimulation, the superficial anodal electrode of the device was placed on the P3 region (left PPC), which is located in the left superior parietal lobe, corresponds to Brodmann area (BA) 40, and is associated with the dorsal visual pathway according to the international 10-20 EEG system.
The reference electrode was placed on the contralateral (opposite) shoulder.
|
|
Comparateur factice: Sham tDCS Group
|
Sham tDCS Protocol: The anode superficial electrode of the device was placed on the P3 region (left PPC), located in the left superior parietal lobe, corresponding to Brodmann area (BA) 40, and associated with the dorsal visual pathway according to the international 10-20 EEG system.
The reference electrode was placed on the contralateral (opposite) shoulder.
In the Sham tDCS group, a single 20-minute sham session was administered over the left posterior parietal cortex (P3) without delivering current, in accordance with the safety guidelines.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
EEG recording and power in alpha band
Délai: Before and immediately after applying tDCS
|
EEG recordings were acquired in a semi-dark, electrically shielded Faraday room using a BrainAmp 32-Channel DC System (Brain Products, Munich, Germany).
Signals were sampled at 500 Hz with a 0.01-250 Hz bandpass filter and recorded using BrainVision Recorder software.
A 32-channel Ag/AgCl electrode cap (Easycap) was positioned according to the international 10-20 system.
Resting-state EEG data were collected for 4 minutes with eyes open and 4 minutes with eyes closed.
Numerical evaluation of artifact-free EEG data for power density calculation is performed using Fast Fourier Transform (FFT) with 0.5 Hz frequency resolution, and alpha (8-13 Hz) bands were calculated and then averaged over these power spectrum values.
The amplitude values, measured from peak to peak, were recorded for each individual, and the necessary data for statistical analysis were collected.
|
Before and immediately after applying tDCS
|
|
Cancellation Test
Délai: Before and immediately after applying tDCS
|
The Cancellation Test is one of the most widely used tools for assessing visuospatial attention.
IT consists of four subtests arranged on A4-sized sheets.
Each subtest includes 60 target stimuli distributed among 300 total stimuli.
For each subtest, separate scores are calculated for the right and left sides, including the number of correctly marked targets (IT1), omitted targets (IT2), incorrectly marked letters/shapes (IT3), total error score (IT4), and scanning time (IT5).
The total error score is calculated as the sum of omitted targets and incorrectly marked letters/shapes.
Achieving a high score (i.e., a high number of correctly marked targets and a low number of errors) and a short completion time (time score) indicate better performance.
İn the present study, the paper-and-pencil version of the Cancellation Test was chosen to reliably assess visuospatial attention and subtle tDCS-induced changes.
|
Before and immediately after applying tDCS
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Lütfü Hanoğlu, Professor, Medipol University
- Chaise d'étude: Mevhibe Sarıcaoğlu, PhD, Medipol University
- Directeur d'études: Miray Budak, PhD, Rutgers University-Newark
- Chaise d'étude: Fatma Aydın, MsC, Medipol University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- E-10840098-772.02-605
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .